Aura Biosciences (NASDAQ:AURA – Get Rating) posted its earnings results on Wednesday. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.
Aura Biosciences Price Performance
Shares of AURA opened at $10.21 on Friday. Aura Biosciences has a one year low of $9.43 and a one year high of $24.83. The stock has a 50-day moving average price of $10.55 and a 200 day moving average price of $12.30.
Analysts Set New Price Targets
Separately, JMP Securities dropped their price target on shares of Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Thursday.
Insiders Place Their Bets
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in AURA. BNP Paribas Arbitrage SNC bought a new position in shares of Aura Biosciences during the third quarter worth about $105,000. American International Group Inc. raised its stake in Aura Biosciences by 208.3% during the second quarter. American International Group Inc. now owns 8,577 shares of the company’s stock valued at $122,000 after buying an additional 5,795 shares in the last quarter. Renaissance Technologies LLC bought a new position in Aura Biosciences during the 4th quarter worth approximately $138,000. JPMorgan Chase & Co. grew its position in shares of Aura Biosciences by 272.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,798 shares of the company’s stock worth $139,000 after acquiring an additional 7,170 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of Aura Biosciences in the 2nd quarter valued at approximately $190,000. 55.63% of the stock is owned by institutional investors and hedge funds.
About Aura Biosciences
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- Dollar General Offers Great Prices, but the Stock isn’t a Value
- Jabil Inc.: Blue Chip Tech Stock Pulls Back To Buy Zone
- Should You Bring The Luck Of The Irish To Your Investmets?
- The Big Banks Join Forces to Save First Republic Bank
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.